Effects of anticoagulants on porcine hepatocytes in vitro: Implications in the porcine hepatocyte-based bioartificial liver

International Journal of Artificial Organs

Volumn 22, Issue 5, 1999, Pages 329-333

  Eguchi, S ^a   Kawazoe, Y ^a   Sugiyama, N ^a   Kawashita, Y ^a   Fujioka, H ^a   Furui, J ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticoagulant; Bioartificial liver; Hepatocytes

Indexed keywords

SODIUM COMPOUNDS;

ANTICOAGULANT; BIOARTIFICIAL LIVER; CLINICAL TREATMENTS; CYTOCHROMES P450; EXTRACORPOREAL SYSTEMS; FOETAL CALF SERUMS; HEPATOCYTES; IN-VITRO; LACTATE DEHYDROGENASE; SODIUM CITRATE;

ARTIFICIAL ORGANS;

(6 AMIDINO 2 NAPHTHYL) 4 GUANIDINOBENZOATE DIMETHANSULFONATE; ALBUMIN; ANTICOAGULANT AGENT; ANTITHROMBIN III; CITRATE SODIUM; HEPARIN; LACTATE DEHYDROGENASE; LIDOCAINE; NAFAMSTAT MESILATE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; ARTIFICIAL LIVER; ARTIFICIAL MEMBRANE; BLOOD CLOTTING; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL VIABILITY; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME RELEASE; EXTRACORPOREAL CIRCULATION; LIVER CELL; LIVER FAILURE; NONHUMAN; PLASMAPHERESIS; SWINE;

EID: 0032767999     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902200507     Document Type: Article

References (19)

1. Watanabe F, Mullon CJP, Hewitt WR et al. Clinical experience with a bioartificial liver in the treatment of severe failure. Ann Surg 1997; 225: 484-94.
2. Olumide F, Eliashiv A, Kralios N, Norton L, Eiseman B. Hepatic support with hepatocyte suspension in a permeable membrane dialyzer. Surgery 1977; 82: 599-606.
3. Ellis AJ, Hughes RD, Wendon Jaet al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-51.
4. Eguchi S, Chen S, Rozga J, Demetriou AA. Tissue Engineering: Liver. Yearbook of Cell and Tissue Transplantation. Chapter 1996; 24: 247-52.
5. Kamohara Y, Kanematsu T. The usefulness of hollow fiber-type bioartificial liver to treat the pig with acute liver failure. Acta Hepatol Jpn 1997; 73: 271-2.
6. Lepore MJ, Stutman LJ, Bonanno CA, Conklin EF, Robilotti JG Jr, McKenna PJ. Plasmapheresis with plasma exchange in hepatic coma. Arch Intern Med 1972; 129: 900-7.
7. Winikoff S, Glassman MS, Spivak W. Plasmapheresis in a patient with hepatic failure awaiting liver transplantation. J Pediatr 1985; 107: 547-9.
8. Hughes RD, Williams R. Use of sorbent columns and hemofiltration in fulminant hepatic failure. Blood Purif 1993; 11: 163-9.
9. Ash SR, Carr DJ, Blake DE et al. Hemodiabsorption in the treatment of acute hepatic failure. ASAIO J 1993; 39: M675-M680.
10. Estes JW. The fate of heparin in the body. Curr Ther Res Clin Exp 1975; 18: 45-57.
11. Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thromb Diath Haemorrh 1975; 33: 26-37.
12. Estes JW. The laboratory control of heparin therapy. Curr Ther Res Clin Exp 1975; 18: 58-65.
13. Bunker JP. Hernodynamic effect intravenously administered sodium citrate. N Engl J Med 1962; 226: 372.
14. Rozga J, Lepage E, Moscioni AD et al. Clinical use of a bioartificial liver to treat fulminant hepatic failure. Ann Surg 1993; 219: 538-46.
15. Aoyama T, Ino Y, Ozeki M et al. Pharmacological studies of FUT-175, nafamostat mesilate. Inhibition of protease activity in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35: 203-27.
16. Kawazoe Y, Eguchi S, Sugiyama N et al. Protective effects of nafamostat mesilate on injury of porcine hepatocytes in human plasma. Cell Transplant (in press).
17. Seglen PO. Preparation of isolated rat liver cells. Meth Cell Biol 1976; 13: 29-83.
18. Lowry OH, Rosebough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
19. Morgan ET. Regulation of cytochromes p450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129-88.